Imanol Arozarena

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/645505/publications.pdf

Version: 2024-02-01

32 papers	2,391 citations	304368 22 h-index	433756 31 g-index
32 all docs	32 docs citations	32 times ranked	4385 citing authors

#	Article	IF	Citations
1	Phenotype plasticity as enabler ofÂmelanoma progression and therapyÂresistance. Nature Reviews Cancer, 2019, 19, 377-391.	12.8	262
2	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. Cell Reports, 2017, 20, 1818-1829.	2.9	220
3	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell, 2016, 29, 270-284.	7.7	198
4	Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating the cGMP-Specific Phosphodiesterase PDE5A. Cancer Cell, 2011, 19, 45-57.	7.7	190
5	FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCÉ›, B-Raf and S6K2. EMBO Journal, 2006, 25, 3078-3088.	3.5	173
6	Microphthalmiaâ€associated transcription factor in melanoma development and <scp>MAP</scp>â€kinase pathway targeted therapy. Pigment Cell and Melanoma Research, 2015, 28, 390-406.	1.5	168
7	Distinct Utilization of Effectors and Biological Outcomes Resulting from Site-Specific Ras Activation: Ras Functions in Lipid Rafts and Golgi Complex Are Dispensable for Proliferation and Transformation. Molecular and Cellular Biology, 2006, 26, 100-116.	1.1	110
8	Overcoming resistance to BRAF inhibitors. Annals of Translational Medicine, 2017, 5, 387-387.	0.7	109
9	Differences on the Inhibitory Specificities of H-Ras, K-Ras, and N-Ras (N17) Dominant Negative Mutants Are Related to Their Membrane Microlocalization. Journal of Biological Chemistry, 2003, 278, 4572-4581.	1.6	102
10	Ras Subcellular Localization Defines Extracellular Signal-Regulated Kinase 1 and 2 Substrate Specificity through Distinct Utilization of Scaffold Proteins. Molecular and Cellular Biology, 2009, 29, 1338-1353.	1.1	100
11	Activation of H-Ras in the Endoplasmic Reticulum by the RasGRF Family Guanine Nucleotide Exchange Factors. Molecular and Cellular Biology, 2004, 24, 1516-1530.	1.1	87
12	Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma. Journal of the National Cancer Institute, 2013, 105, 33-46.	3.0	85
13	The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. Frontiers in Cell and Developmental Biology, 2016, 4, 33.	1.8	84
14	An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. Journal of Experimental Medicine, 2017, 214, 1691-1710.	4.2	71
15	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Molecular Medicine, 2017, 9, 1011-1029.	3.3	63
16	H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism. Oncogene, 2000, 19, 783-790.	2.6	53
17	Ras, an Actor on Many Stages: Posttranslational Modifications, Localization, and Site-Specified Events. Genes and Cancer, 2011, 2, 182-194.	0.6	49
18	Glucose availability controls ATF4-mediated MITF suppression to drive melanoma cell growth. Oncotarget, 2017, 8, 32946-32959.	0.8	46

#	Article	IF	Citations
19	The Rho Family GTPase Cdc42 Regulates the Activation of Ras/MAP Kinase by the Exchange Factor Ras-GRF. Journal of Biological Chemistry, 2000, 275, 26441-26448.	1.6	40
20	MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide. Molecular Cancer Therapeutics, 2015, 14, 1236-1246.	1.9	36
21	Targeting invasive properties of melanoma cells. FEBS Journal, 2017, 284, 2148-2162.	2.2	36
22	Maintenance of Cdc42 GDP-bound State by Rho-GDI Inhibits MAP Kinase Activation by the Exchange Factor Ras-GRF. Journal of Biological Chemistry, 2001, 276, 21878-21884.	1.6	32
23	RAS at the Golgi antagonizes malignant transformation through PTPRÎº-mediated inhibition of ERK activation. Nature Communications, 2018, 9, 3595.	5.8	18
24	Cooperative behaviour and phenotype plasticity evolve during melanoma progression. Pigment Cell and Melanoma Research, 2020, 33, 695-708.	1.5	18
25	Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?. Cancers, 2021, 13, 5799.	1.7	18
26	Identification of a Dexamethasone Mediated Radioprotection Mechanism Reveals New Therapeutic Vulnerabilities in Glioblastoma. Cancers, 2021, 13, 361.	1.7	8
27	Understanding the Molecular Mechanism of miR-877-3p Could Provide Potential Biomarkers and Therapeutic Targets in Squamous Cell Carcinoma of the Cervix. Cancers, 2021, 13, 1739.	1.7	4
28	Targeting MITF in the tolerance-phase. Oncotarget, 2016, 7, 54094-54095.	0.8	4
29	Novel Insights into the Role of the Mineralocorticoid Receptor in Human Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 11656.	1.8	3
30	Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. Molecular Cancer, 2014, 13, 154.	7.9	2
31	Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. Pancreatology, 2021, 21, 215-223.	0.5	2
32	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). Annals of Translational Medicine, 2017, 5, 390-390.	0.7	0